GFA
UTHR icon

Gallagher Fiduciary Advisors’s United Therapeutics UTHR Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Sell
568
-23
-4% -$13K 0.01% 290
2026
Q1 		$350K Buy
591
+18
+3% +$8.96K 0.01% 244
2025
Q4 		$279K Buy
573
+35
+7% +$16.3K 0.01% 280
2025
Q3 		$225K Buy
+538
New +$181K 0.01% 285

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Gallagher Fiduciary Advisors's UTHR Position: Q2 2026 in Review

Gallagher Fiduciary Advisors reduced its United Therapeutics (UTHR) stake by 3.9% in Q2 2026, selling an estimated $13K and leaving 568 shares worth $307K. The position accounts for 0.01% of the portfolio, ranked #290.

Gallagher Fiduciary Advisors first reported a position in UTHR in Q3 2025 and has held it in 4 quarters since. The position peaked at $350K in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Gallagher Fiduciary Advisors held 568 shares of United Therapeutics worth $307K as of Q2 2026.
  • Gallagher Fiduciary Advisors sold 23 United Therapeutics shares in Q2 2026, an estimated $13K.
  • United Therapeutics made up 0.01% of Gallagher Fiduciary Advisors's portfolio in Q2 2026, its #290 holding.
  • Gallagher Fiduciary Advisors first reported a position in United Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Gallagher Fiduciary Advisors's United Therapeutics position peaked at $350K in Q1 2026.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Gallagher Fiduciary Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.